Safety of Ramucirumab Regimen Without H1-antihistamine Premedication in Patients With Solid Cancers

Conclusion: Although our data are preliminary and limited, H1AT-free RAM regimens may be a treatment option for cancer patients having a significant risk of developing H1AT-related side effects. Further studies are needed to confirm the safety of H1AT-free RAM regimens.

Source: In Vivo - November 3, 2020 Category: Research Authors: GOTO, E., YAMAGUCHI, T., HATTORI, N., GOTO, M., NISHIHARA, M., UCHIYAMA, K., RIKITAKE, Y. Tags: Clinical Studies Source Type: research